Premium
Effect of recombinant feline interferon‐ω alone and in combination with chemotherapeutic agents on putative tumour‐initiating cells and daughter cells derived from canine and feline mammary tumours
Author(s) -
Penzo C.,
Ross M.,
Muirhead R.,
Else R.,
Argyle D. J.
Publication year - 2009
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2009.00192.x
Subject(s) - cell culture , mammary carcinoma , cancer research , biology , cell , anthracycline , interferon , in vitro , microbiology and biotechnology , carcinoma , cancer , immunology , breast cancer , biochemistry , genetics
Interferons (IFNs) are naturally produced cytokines with multiple important biological functions. The activity of recombinant feline IFN‐ω (rFeIFN‐ω) alone and in combination with chemotherapeutic drugs was tested on canine and feline mammary carcinoma cell lines (REM134 and CAT‐MT) and putative tumour‐initiating cells (TIC) derived from these cell lines by sphere assay. Viability was measured by chemoluminescence and a one‐way analysis of variance and Student's t ‐tests were used for statistical analysis. rFeIFN‐ω showed in vitro antitumour activity on feline and canine mammary carcinoma cells and putative TICs with a dose‐dependent and target cell‐specific action. Putative TICs were more resistant to the action of rFeIFN‐ω compared with daughter REM134 and CAT‐MT cells. REM134 cells and TICs were more sensitive to rFeIFN‐ω compared with the feline counterparts. An additive effect was noticed between rFeIFN‐ω and conventional anticancer drugs, in particular following co‐culture of cells with anthracycline drugs. The results suggest that rFeIFN‐ω warrants further investigation as a therapeutic adjunct in feline and canine mammary tumours.